Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Gains from Investment Securities (2020 - 2025)

Historic Gains from Investment Securities for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Q3 2025 value amounting to $3.4 million.

  • Insight Molecular Diagnostics' Gains from Investment Securities fell 5268.91% to $3.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.6 million, marking a year-over-year decrease of 13219.94%. This contributed to the annual value of -$4.3 million for FY2024, which is 2580.7% up from last year.
  • Latest data reveals that Insight Molecular Diagnostics reported Gains from Investment Securities of $3.4 million as of Q3 2025, which was down 5268.91% from $2.8 million recorded in Q2 2025.
  • Over the past 5 years, Insight Molecular Diagnostics' Gains from Investment Securities peaked at $25.0 million during Q4 2021, and registered a low of -$18.3 million during Q1 2023.
  • Moreover, its 5-year median value for Gains from Investment Securities was $879000.0 (2025), whereas its average is -$354157.9.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first skyrocketed by 613529.41% in 2021, then crashed by 2129666.67% in 2022.
  • Insight Molecular Diagnostics' Gains from Investment Securities (Quarter) stood at $25.0 million in 2021, then tumbled by 155.43% to -$13.9 million in 2022, then skyrocketed by 180.69% to $11.2 million in 2023, then tumbled by 222.45% to -$13.7 million in 2024, then soared by 124.66% to $3.4 million in 2025.
  • Its Gains from Investment Securities was $3.4 million in Q3 2025, compared to $2.8 million in Q2 2025 and $879000.0 in Q1 2025.